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http://www.biomedcentral.com/1471-2407/12/436RESEARCH ARTICLE Open AccessEvidence for different mechanisms of ‘unhooking’
for melphalan and cisplatin-induced DNA
interstrand cross-links in vitro and in clinical
acquired resistant tumour samples
Victoria J Spanswick1, Helen L Lowe1, Claire Newton1, John P Bingham1, Alessia Bagnobianchi1,
Konstantinos Kiakos1, Charles Craddock2, Jonathan A Ledermann3, Daniel Hochhauser1 and John A Hartley1*Abstract
Background: DNA interstrand cross-links (ICLs) are critical lesions produced by several cancer chemotherapy agents
including platinum drugs and nitrogen mustards. We have previously shown in haematological (multiple myeloma)
and solid tumours (ovarian cancer) that clinical sensitivity to such agents can result from a defect in DNA ICL
processing leading to their persistence. Conversely, enhanced repair can result in clinical acquired resistance following
chemotherapy. The repair of ICLs is complex but it is assumed that the ‘unhooking’ step is common to all ICLs.
Methods: Using a modification of the single cell gel electrophoresis (Comet) assay we measured the formation
and unhooking of melphalan and cisplatin-induced ICLs in cell lines and clinical samples. DNA damage response in the
form of γ-H2AX foci formation and the formation of RAD51 foci as a marker of homologous recombination were also
determined. Real-time PCR of 84 genes involved in DNA damage signalling pathways was also examined pre- and
post-treatment.
Results: Plasma cells from multiple myeloma patients known to be clinically resistant to melphalan showed significant
unhooking of melphalan-induced ICLs at 48 hours, but did not unhook cisplatin-induced ICLs. In ovarian cancer cells
obtained from patients following platinum-based chemotherapy, unhooking of cisplatin-induced ICLs was observed at
48 hours, but no unhooking of melphalan-induced ICLs. In vitro, A549 cells were proficient at unhooking both
melphalan and cisplatin-induced ICLs. γ-H2AX foci formation closely followed the formation of ICLs for both drugs, and
rapidly declined following the peak of formation. RPMI8226 cells unhooked melphalan, but not cisplatin-induced ICLs.
In these cells, although cross-links form with cisplatin, the γ-H2AX response is weak. In A549 cells, addition of 3nM
gemcitabine resulted in complete inhibition of cisplatin-induced ICL unhooking but no effect on repair of melphalan
ICLs. The RAD51 foci response was both drug and cell line specific. Real time PCR studies highlighted differences in the
damage response to melphalan and cisplatin following equi-ICL forming doses.
Conclusions: These data suggest that the mechanisms by which melphalan and cisplatin-induced ICLs are ‘unhooked’
in vitro are distinct, and the mechanisms of clinical acquired resistance involving repair of ICLs, are drug specific.
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DNA cross-linking agents such as the nitrogen mustards
(melphalan, chlorambucil, cyclophosphamide, ifosfa-
mide), platinum drugs (cisplatin, carboplatin, oxalipla-
tin), chloroethylnitrosoureas (carmustine, lomustine),
the alkylalkane sulphonate busulphan and the natural
product mitomycin C are widely used drugs as both sin-
gle agents (including in a high-dose setting) and as com-
ponents of many combination chemotherapy regimens
[1,2]. In addition, more selective cross-linking agents
such as SJG-136 (SG2000) continue to be developed
[3,4]. Bi-functional covalent modification (cross-linking)
of DNA is essential for antitumor activity with these
drugs [5,6]. In particular, the DNA interstrand cross-link
(ICL) which covalently links together bases on opposite
strands of the DNA helix, and which normally only ac-
count for a small proportion (1-10%) of total DNA
adducts, present a serious threat to cellular survival
because they inhibit fundamental processes such as
DNA replication and transcription [1,7]. There is clear
evidence that the formation and subsequent persistence
of ICLs correlates with in vitro cytotoxicity [8,9].
In a previous study, using a modification of the single
cell gel electrophoresis (Comet) assay, we measured for-
mation and repair of DNA ICLs in plasma cells from
melphalan-naïve and melphalan-treated patients (i.e.
those who had relapsed after a melphalan-conditioned
autologous stem cell transplant or oral melphalan ther-
apy) [9]. Similar levels of dose-dependent DNA ICLs
were observed in cells from both melphalan-naïve and
treated patients. However, marked differences in ICL
repair were observed: cells from naïve patients had
no repair, whereas those from treated patients exhibited
between 42-100% repair at 40 hours. In vitro sensitivity
to melphalan in plasma cells was found to correlate with
ICL repair. These findings suggest that a defect in ICL
repair may contribute to the initial sensitivity to melpha-
lan and that ICL repair may be an important mechanism
by which melphalan acquired resistance emerges in the
clinic [10,11].
In a second study we examined ICL formation and re-
pair in tumour cells isolated from fifty ovarian cancer
patients [12]. No significant difference in the peak level
of ICL formation in tumour cells was observed between
patients who were either newly diagnosed, or previously
treated with, platinum-based chemotherapy (or between
tumour and mesothelial cells from the same patient).
In contrast, the repair of ICLs was much greater in the
group of treated patients. In eight patients it was pos-
sible to obtain tumour samples prior to any chemo-
therapy, and also at relapse or at interval de-bulking
surgery following platinum chemotherapy. In these
patients the mean % repair prior to therapy was 2.85
rising to 71.23 following treatment. These data againsuggest that inefficient repair of ICLs contributes to the
initial clinical sensitivity, and that increased ICL repair
contributes to clinical acquired resistance.
Repair of ICLs is complex and requires the concerted
action of multiple pathways [7,13,14]. Although the
exact molecular mechanisms have yet to be fully eluci-
dated, it is clear that incision around the lesion to allow
‘unhooking’ of the ICL from one of the two DNA
strands represents a pivotal step in the repair process as
it relieves the torsional stress an ICL imposes on the
DNA helix and permits processing of the repair inter-
mediates by downstream pathways. This is the step in
ICL repair that can be measured using the modification
of the comet assay since it detects the ability of the
DNA strands to separate under alkaline conditions. A
number of nucleases have been suggested to play such a
role in this unhooking step, including the XPF-ERCC1
complex [5,15,16] and the Fanconi anaemia pathway
orchestrates incisions at sites of crosslinked DNA (re-
cently reviewed in [17]. Regardless of the exact mechan-
ism of unhooking, it is widely assumed that this
unhooking step will be common to all DNA ICLs. In this
study, however, we present evidence in vitro and in clin-
ical samples with acquired resistance that the mechan-
isms of unhooking for melphalan and cisplatin-induced
ICLs are distinct.
Methods
Cell lines and peripheral blood lymphocytes
A549 and RPMI8226 cell lines were purchased from the
European Collection of Cell Cultures (ECACC). The
human ovarian cancer cell line A2780 was established
from tumour tissue from an untreated patient [18].
Growing A2780 cells in cisplatin and selecting for cis-
platin resistance generated the stably resistant A2780cisR
cell line. Both cell lines were obtained from Dr Swee
Sharp, Institute of Cancer Research, Sutton, UK.
RPMI8226 cells was maintained in RPMI1640 media
containing 2 mM L-glutamine and 10% foetal calf serum
(FCS). A549 was maintained in Dulbecco’s Modified
Eagles Medium (DMEM) containing 2 mM L-glutamine
and 10% FCS. All cell lines were maintained in a humidi-
fied atmosphere at 37°C with 5% carbon dioxide (CO2)
and maintained in exponential growth. The cells were kept
at low passage, returning to original frozen stocks every
3 to 6 months, and tested regularly for Mycoplasma.
Peripheral blood lymphocytes (PBLs) were isolated
using the VacutainerW CPT™ system (Becton Dickinson,
Oxford, UK). Samples were centrifuged at 1500 g for
20 minutes at room temperature. The fluffy mono-
nuclear layer at the interface of the two layers was
removed using a Pasteur pipette and transferred to a
15 ml tube. 10 ml cold RPMI 1640 tissue culture media
was then added and the tube gently inverted and
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The supernatant was then discarded and the cell pellet
re-suspended in RPMI 1640 containing 10% foetal calf
serum and 2 mM L-glutamine.
Patient samples
Plasma cells were isolated from bone marrow taken from
Multiple Myeloma patients using standard Ficoll-Hypaque
[10]. Patients 1 and 2 had relapsed following vincristine,
adriamycin and dexamethasome (VAD) chemotherapy,
received a melphalan conditioned (200 mg/m2) autologous
stem cell transplant and were known to be clinically mel-
phalan resistant. All samples studied contained in excess
of 80% plasma cells.
Ovarian cancer tumour cells taken from ovarian can-
cer patients either pre- or post-platinum based chemo-
therapy, were isolated from ascitic fluid as described
in detail elsewhere [12]. Ethics approval was gained
from the Joint UCL/UCLH Committee on the Ethics
of Human Research. In order to separate tumour cells
from non-tumour mesothelial cells, ascitic fluid was
centrifuged at 200 g for 5 minutes. Cell pellets were re-
suspended in DMEM containing 10% FCS and 2 mM L-
glutamine and seeded into large tissue culture flasks and
incubated in a humidified atmosphere at 37°C with 5%
CO2. After 1 hour, the entire volume of tissue culture
medium in each flask containing unattached cells was
transferred into a fresh tissue culture flask and DMEM
containing 10% FCS and 2 mM L-glutamine was
replaced in the original flasks. Normal mesothelial cells
attached to the plastic surface within the first hour,
where as tumour cells required a longer period of
time to detach in response to trypsin. Further purifica-
tion of the tumour samples were achieved using trypsini-
sation until the contaminant mesothelial cells were seen
to detach, while the tumour cells remained in situ.
Drug treatment
Cell lines, PBLs and patient samples were incubated with
either melphalan (Sigma Chemical Co., Poole, U.K.) or
cisplatin (David Bull Laboratories, Australia) for 1 hour
at 37°C and 5% CO2 in a humidified atmosphere. For
RPMI8226 cell line, PBLs and myeloma plasma cells, the
drug was removed by centrifugation at 200 g for 5 min-
utes, the supernatant removed and cells re-suspended in
drug-free full media. Cells were then incubated at 37°C
and 5% CO2 in a humidified atmosphere. For A549,
A2780, A2780cisR cell lines and patient ovarian tumour
cells isolated from ascitic fluid, drug treatments were
carried out in 6-well plates and the media replaced with
drug free medium following treatment. In order to as-
sess DNA interstrand cross-linking and repair, samples
were taken at various time points following the 1 hour
drug incubation. For combination experiments, cellswere treated with 3nM gemcitabine (Eli Lilly & Com-
pany, Basingstoke, U.K.) in combination with melphalan
or cisplatin. Both drugs were removed as described
above and cells incubated with 3nM gemcitabine for the
remainder of the incubation period.
Determination of DNA interstrand cross-link formation
and its repair using the single cell gel electrophoresis
(comet) assay
The details of the single cell gel electrophoresis (comet)
assay used to measure DNA interstrand cross-linking
and repair are described in detail elsewhere [19]. All pro-
cedures were carried out on ice and in subdued lighting.
All chemicals were obtained from Sigma Chemical Co.
(Poole, U.K.) unless otherwise stated. Immediately before
analysis cells were diluted to give a final concentration
of 2.5 x104 cells/mL and irradiated (15 Gy) in order to
deliver a fixed number of random DNA strand breaks.
After embedding cells in 1% agarose on a pre-coated
microscope slide, the cells were lysed for 1 hour in lysis
buffer (100 mM disodium EDTA, 2.5 M NaCl, 10 mM
Tris–HCl pH 10.5) containing 1% Triton X-100 added
immediately before analysis, and then washed every
15 minutes in distilled water for 1 hour. Slides were then
incubated in alkali buffer (50 mM NaOH, 1 mM diso-
dium EDTA, pH12.5) for 45 minutes followed by elec-
trophoresis in the same buffer for 25 minutes at 18 V
(0.6 V/cm), 250 mA. The slides were finally rinsed in
neutralising buffer (0.5 M Tris–HCl, pH 7.5) then saline.
After drying the slides were stained with propidium
iodide (2.5 μg/mL) for 30 minutes then rinsed in dis-
tilled water. Images were visualised using a NIKON
inverted microscope with high-pressure mercury light
source, 510-560 nm excitation filter and 590 nm barrier
filter at x20 magnification. Images were captured using
an on-line CCD camera and analysed using Komet Anal-
ysis software 4.02 (Andor Technology, U.K.). For each
duplicate slide 25 cells were analysed. The tail moment
for each image was calculated as the product of the per-
centage DNA in the comet tail and the distance between
the means of the head and tail distributions [20]. DNA
interstrand cross-linking was expressed as percentage
decrease in tail moment compared to irradiated controls
calculated by the formula:
% decrease in tail moment ¼ 1 TMdi TMcuð Þ
TMci TMcuð Þ
  
x100
Where TMdi = tail moment of drug-treated irradiated
sample; TMcu = tail moment of untreated, unirradi-
ated control; TMci = tail moment of untreated, irra-
diated control.
In cells treated with DNA cross-linking agents and
gemcitabine in combination, cross-linking was expressed
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diated controls calculated by the formula below. This
formula was used to compensate for the additional sin-
gle strand breaks induced by gemcitabine in addition to
those produced by the irradiation step.
% decrease in tail moment
¼ 1 TMdi TMcuð Þ
TMci TMcuð Þ þ TMdu TMcuð Þ
  
x100
Where TMdi = tail moment of drug-treated irradiated
sample; TMcu = tail moment of untreated, unirradi-
ated control; TMci = tail moment of untreated, irra-
diated control.
In both multiple myeloma and ovarian patient samples,
percentage repair was calculated at 48 hours following
the peak of DNA interstrand cross-linking (9 hours for
cisplatin [12] and 16 hours for melphalan [10]).
Measurement of γ-H2AX and RAD51 foci by
immunofluorescence
For the A549 cell line, 8 x 104 cells per well were seeded
in a 2 well LAB-TEKW II chamber slides™ (Nalgene
Nunc International, Hereford, UK) and incubated over-
night at 37°C. Cells were treated with either 2 μM
melphalan or 5 μM cisplatin for 1 hour after which the
drug was removed and cells incubated at 37°C in drug-
free medium.
For the RPMI8226 cell line, cells were treated with ei-
ther 2 μM melphalan or 5 μM cisplatin for 1 hour after
which the drug was removed by centrifugation at 200 g,
cells re-suspended and incubated at 37°C in drug-free
medium. At the required time point, 10 x104 cells were
adhered to Vision BioSystems™ Plus slides by cytospin-
ning at 650 rpm for 5 minutes at room temperature.
Slides were then dried at room temperature.
For both cell lines, cells were fixed with ice cold
methanol: acetone (50:50) for 15 min at 4°C. Cells were
washed 3 times with cold PBS then permeabilized with
0.5% Triton X-100 in PBS for 15 min at room
temperature. Cells were then blocked overnight at 4°C
with blocking buffer (0.1% Triton X-100, 0.2% skimmed
dry milk in PBS). Blocked cells were incubated overnight
at 4°C with either anti-phospho-histone H2A.X (Ser139)
monoclonal antibody (Millipore, U.K) at a 1:1000 dilu-
tion or anti-RAD51 (H-92) polyclonal antibody (Santa
Cruz Biotechnology Inc) at a 1:100 dilution in blocking
buffer. After washing 3 times with wash buffer (0.1%
Triton X-100 in PBS), cells were then incubated for
4 hours at room temperature with Alexa FluorW 488
goat anti-mouse secondary antibody (InVitrogen, UK)
for γH2AX staining or Alexa FluorW 488 goat anti-rabbit
secondary antibody (InVitrogen, UK) for RAD51 stain-
ing, at a dilution of 1:1000 and 1:200 respectively inblocking buffer. Cells were then washed with PBS. For γ-
H2AX, cells were counterstained with 2 μg/mL propi-
dium iodide for 2 min. Slides were then rinsed in dis-
tilled water for 30 minutes, mounted with VectashieldW
(Vector Laboratories, Peterborough, UK) and the edges
sealed with clear nail polish. For RAD51, slides were
mounted with VectashieldW with DAPI and the edges
sealed with clear nail varnish. Images were visualised
using Perkin Elmer Ultraview ERS Suite v 3.0.0 and con-
focal microscopy consisting of Zeiss Axiovert 200
inverted fluorescence microscope (x40 oil objective)
equipped with 14 bit ECCD camera and argon and kryp-
ton gas excitation lasers at 488 nm and 568 nm. Foci
were counted in 50 cells per time point and results are
expressed as mean number of foci per cell from three
independent experiments.
Real-time PCR of genes involved in DNA damage
signalling pathways
Exponentially growing cells were treated for 1 hour with
either 150 μM cisplatin or 50 μM melphalan after which
the drug was removed and replaced with drug free
media. Cells were then incubated for 9 hours (cisplatin)
and 16 hours (melphalan) post-treatment to allow max-
imum formation of interstrand cross-links. Cells were
then trypsinised, washed with PBS and pelleted and
stored at -80°C prior to analysis.
Total RNA was extracted from the cell pellets using a
RNEasy kit (Qiagen) according to the manufacturers
protocol and concentration measured. Template cDNA
was generated from 1 μg of RNA using the RT2 First
Strand Kit (SABiosciences-Qiagen). This template cDNA
was then amplified in 25 μl volumes using the DNA
Damage Signalling Pathway PCR Array and RT2 qPCR
Mastermix (SABiosciences-Qiagen). Amplification was
carried out in an Applied Biosystems 7500 RT-PCR
machine. The RT-PCR condition was an initial incuba-
tion at 95°C for 10 minutes followed by 45 cycles at
95°C (15 seconds) and 60°C (1 minute).
Cycle Threshold (CT) values were automatically calcu-
lated using Applied Biosystems SDS software and
changes in gene expression were then analysed using the
online web application at http://www.sabiosciences.com/
pcr/arrayanalysis.php.
The Functional Gene Groupings and Gene Table are
shown in Supplementary Material.
Results and discussion
Different mechanisms of ‘unhooking’ of DNA ICLs in
clinical acquired resistant tumour samples
We have previously shown that plasma cells from mye-
loma patients prior to any chemotherapy treatment are
defective in ‘unhooking’ melphalan-induced ICLs when
treated ex vivo, whereas cells from patients following
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Figure 1 Unhooking of DNA ICLs produced by melphalan or
cisplatin in clinical samples measured using the single cell gel
electrophoresis (comet) assay. A: Plasma cells from two multiple
myeloma patients clinically resistant to melphalan. Cells were treated
ex vivo for 1 hour with either 150 μM cisplatin or 50 μM melphalan
after which the drug was removed and replaced with drug free
media. Cells were then incubated for 9 hours (cisplatin, blue) or
16 hours (melphalan, red) post-treatment to allow maximum
formation of interstrand cross-links. The level of ICL at this time
point was compared to a second sample incubated for a total of
48 hours to obtain the % repair. B: As above but in tumour samples
from ovarian cancer patients. In this case the two patients provided
samples on initial diagnosis and prior to any platinum-based
chemotherapy (Pre) and again following relapse on platinum-based
therapy (Post).
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are proficient in unhooking melphalan ICLs [10]. We
examined the ability of plasma cells from two repre-
sentative melphalan resistant patients to unhook the
ICLs produced by cisplatin, in addition to melphalan
(Figure 1A). Cells were treated ex vivo with either mel-
phalan (50 μM) or cisplatin (150 μM) for 1 hour, drug
removed and the level of ICLs measured with time using
the established modification of the single cell gel electro-
phoresis (comet) assay [19]. The decrease in level of
ICLs at 48 hour (expressed as the % repair at 48 hours
in Figure 1A) was compared to the 16 hour (melphalan)
and 9 hour (cisplatin) levels, which we have previously
shown to be the time of peak ICL for these agents
[10,12]. In both these patient samples a significant repair
(unhooking) of melphalan-induced ICLs was observed
(40% in patient 1 and 58% in patient 2), as has been
observed previously [10]. In contrast, no unhooking of
cisplatin-induced ICLs was observed at 48 hours in ei-
ther patient sample. In fact, in the cells from patient 2,
the level of ICLs at 48 hours was slightly higher than at
9 hours resulting in the negative ‘repair’ value.
In a further two patient samples that showed 30% and
14% unhooking of melphalan-induced ICLs, no unhook-
ing of cisplatin-induced ICLs was observed. Cells from a
melphalan naïve patient showed no repair of ICLs pro-
duced by either drug.
The ability of cancer cells taken from two ovarian can-
cer patients to unhook the ICLs produced by the two
drugs was then examined. In these patients it was pos-
sible to obtain tumour samples at initial diagnosis (be-
fore any chemotherapy) and then again after the patients
had undergone platinum-based chemotherapy. Under
the identical drug-treatment conditions used in
Figure 1A, the initial cells (Pre) from neither patient
were able to unhook the ICLs produced by melphalan or
cisplatin up to 48 hours (Figure 1B). In contrast, the
tumour cells from both patients taken after platinum-
based chemotherapy (Post) showed efficient unhooking
of cisplatin ICLs (77% and 60% at 48 hours) but no
unhooking of melphalan ICLs.
In total, 12 pre-chemotherapy and 7 post platinum-
based chemotherapy patient samples were tested for
unhooking of melphalan ICLs. The mean % repair
(unhooking) was 4% and 3% for the pre- and post-
chemotherapy patients, respectively. This is in marked
contrast to our previously reported data where mean%
repair of cisplatin ICLs was 3% pre-chemotherapy and
71% post platinum-based chemotherapy [12]. Taken to-
gether, these data suggest that distinct mechanisms are
evoked in the two tumour types in patients following
chemotherapy, resulting in different mechanisms of
unhooking for melphalan and cisplatin-induced ICLs.Differences in unhooking of melphalan and cisplatin-
induced ICLs in human tumour cell lines
We next looked for cell line models that could replicate
the phenotype that we observed in the clinical samples.
The time course of ICL formation and repair was exam-
ined in the human non-small cell lung cancer cell line
A549 following a 1 hour treatment with 50 μM melphalan
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the range of the GI50 values as shown in Additional file:
Table S1) were chosen to be consistent with our data in
clinical samples and to give equivalent peak levels of ICL
by the two agents. Representative comet images are
shown in Figure 2A. In A549 cells, the peak of ICL was at
9 hours for cisplatin and 16 hours for melphalan, and in
these cells the ICLs produced by both agents were effi-
ciently unhooked, resulting in 92% and 81% repair at
48 hours, respectively (Figure 2B). In addition to measur-
ing ICLs using the comet assay, DNA damage response in
the form of γ-H2AX foci formation was also followed
in the same cells (Figure 2C,D). Previous studies from0
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Figure 2 DNA ICL and γ-H2AX foci formation in A549 cells following
comet images from A549 cells either untreated, or treated with 50 μM mel
subsequent 16 hours incubation in drug free medium. B: Cells were treated
(red) after which the drug was removed and replaced with drug free medi
measured using the comet assay. Data are the mean ± s.d. from at least th
γ-H2AX foci following treatment with cisplatin at 5 μM followed by post-in
treated with either 2 μM melphalan (red) or 5 μM cisplatin (blue) for 1 hou
drug-free medium. Samples were taken at different times of post-incubatio
from at least three independent experiments.our laboratory have shown that γ-H2AX foci formation
can be used as a pharmacodynamic indicator of ICL for-
mation for both nitrogen mustard and platinum-based
drugs [21]. γ-H2AX is likely marking sites of double
strand breaks generated after unhooking or lesion proces-
sing by structure specific endonucleases. Doses of drug
used to treat cells for 1 hour were lower than those used
in the comet assay due to the increased sensitivity of this
assay. γ-H2AX foci formation followed the timing of ICL
formation for both drugs, as shown previously in a differ-
ent cell line [21], and rapidly declined following the
peak of formation (Figure 2D). The decline in γ-H2AX
suggests the resolution of the intermediate double0 12 24 36 48
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treatment with either cisplatin or melphalan. A: Representative
phalan for 1 hour. Drug-treated samples shown were following a
for 1 hour with either 150 μM cisplatin (blue) or 50 μM melphalan
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ree independent experiments. C: Representative A549 cells showing
cubation in drug free medium for the times shown. D: Cells were
r after which the drug was removed and cells incubated at 37°C in
n and γ-H2AX foci formation determined. Data are the mean ± s.d.
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http://www.biomedcentral.com/1471-2407/12/436strand breaks by downstream pathways e.g. homologous
recombination repair, translesion DNA synthesis etc. We
previously showed that γ-H2AX foci resulting from nitro-
gen mustard and cisplatin-induced ICLs persisted longer
in homologous recombination defective cells [21].
Identical experiments were performed in the human
myeloma cell line RPMI8226 (Figure 3). In this cell line
the peak of melphalan-induced ICLs was again at
16 hours and significant unhooking was observed within
8 hours (Figure 3A). In contrast, cisplatin ICLs formed
by 9 hours but were not unhooked over a 48 hour
period. This cell line, therefore, was consistent with the
phenotype seen in the melphalan-resistant plasma cells
from patients (Figure 1A). This same phenotype was also
observed in a second myeloma cell line U266 (data not0
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Figure 3 DNA ICL and γ-H2AX foci formation in RPMI8226 cells
following treatment with either cisplatin or melphalan. A: Cells
were treated for 1 hour with either 150 μM cisplatin (blue) or 50 μM
melphalan (red) after which the drug was removed and replaced
with drug free media. Samples were taken at different times of
post-incubation and ICLs measured using the comet assay. Data are
the mean ± s.d. from at least three independent experiments. B:
Cells were treated with either 2 μM melphalan (red) or 5 μM
cisplatin (blue) for 1 hour after which the drug was removed and
cells incubated at 37°C in drug-free medium. Samples were taken at
different times of post-incubation and γ-H2AX foci formation
determined. Data are the mean ± s.d. from at least three
independent experiments.shown). The γ-H2AX foci response in RPMI8226 cells is
shown in Figure 3B. Although the response was weaker
than that seen in A549 cells, γ-H2AX foci showed a
similar response to melphalan, peaking with the forma-
tion of ICLs and then declining rapidly. With cisplatin,
however, although cross-links form, the γ-H2AX response
is extremely weak (Figure 3B). This lack of a significant
DNA damage response is consistent with the lack
of unhooking of the ICLs observed in this cell line, there-
fore preventing the subsequent generation of double
strand breaks.
We then looked in human ovarian cancer cell lines for
a phenotype that would mirror that observed in the clin-
ical situation shown in Figure 1B. A2780 cells gave peak0
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Figure 4 Effect of gemcitabine on the unhooking of cisplatin or
melphalan-induced ICLs in A549 cells. A: Cells were treated for
1 hour with 150 μM cisplatin either alone (blue) or in the presence
of 3nM gemcitabine (green) after which the drugs were removed
and replaced with drug free media, or media containing 3nM
gemcitabine. Samples were taken at different times of post-
incubation and ICLs measured using the comet assay. Data are the
mean ± s.d. from at least three independent experiments. B: Cells
were treated for 1 hour with 50 μM melphalan either alone (red) or
in the presence of 3nM gemcitabine (green) after which the drugs
were removed and replaced with drug free media, or media
containing 3 nM gemcitabine. Samples were taken at different times
of post-incubation and ICLs measured using the comet assay. Data
are the mean ± s.d. from at least three independent experiments.
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http://www.biomedcentral.com/1471-2407/12/436of cross-linking at 9 hours and 16 hours for cisplatin
and melphalan, respectively, as seen in the other cell
lines. These cells were not efficient at unhooking either
type of cross-link giving 0% and 16% repair at 48 hours
for cisplatin and melphalan, respectively (data not shown).
This cell line therefore mirrored the clinical phenotype in
chemotherapy naïve ovarian cancer (Figure 1B). A cis-
platin acquired resistant line (A2780cisR) derived from
A2780 was also examined. In this line the levels of ICLs
produced by cisplatin and melphalan were identical to
those in A2780 indicating that the mechanism of drug re-
sistance could not be attributed to an altered transportM
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This is in contract to other reports in the literature e.g.
Jansen et al. 2002 [22] in which A2780cisR cells are
shown to have elevated glutathione. The A2780cisR cell
line used in the present study differed from the parental
line, however, in that it was now capable of unhooking
the cross-links produced by both agents. Since these cells
efficiently unhook both types of cross-link, it is not repre-
sentative of the phenotype observed clinically where only
cisplatin-induced ICLs were repaired (Figure 1B).
p53 is one of the most important factors in determin-
ing the sensitivity of cells to DNA damage. The A5490
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independent experiments.
Figure 6 (See legend on next page.)
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Figure 6 Real time PCR analysis of the changes in expression of 84 genes involved in DNA damage signalling/repair pathways,
following exposure of cells to ICL agent. A: Prior to RNA extraction, A549 cells were treated with melphalan at 50 μM for 1 hour followed by
16 hours post-incubation to allow peak ICL formation. The mean expression from three individual drug treatment repeat samples are compared
to three individual non-drug treated control samples. Genes which show increased expression by more than 2-fold compared to control cells
following drug treatment are shown in red and those which show decreased expression in green. B: As above, but A549 cells were treated with
cisplatin at 150 μM for 1 hour followed by 9 hours post-incubation to allow peak ICL formation.
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RPMI8226 cell line p53 mutant [24]. Since A549 cells
unhook the ICLs produced by both melphalan and cis-
platin, RPMI8226 cells unhook only melphalan ICLs
and A2780 unhook neither, p53 status does not explain
these findings.
Effect of gemcitabine on the unhooking of cisplatin
and melphalan-induced ICLs
Gemcitabine has previously been shown to act synergis-
tically with cisplatin in vitro [25] and the combination
with platinum drugs is useful clinically [26-28]. We
examined the effect of continuous administration of
3nM gemcitabine on the repair (unhooking) of cisplatin
and melphalan-induced ICLs in A549 cells (Figure 4). In
the case of cisplatin, gemcitabine completely inhibited
the unhooking of ICLs with 0% repair at 48 hours com-
pared to 85% in the absence of gemcitabine (Figure 4A).
We have observed a similar inhibition of repair in lym-
phocytes from patients treated with the combination of
carboplatin and gemcitabine [28] and fludarabine has
been shown to suppress DNA ICL removal in chronic
lymphocytic leukemia lymphocytes [29]. In contrast,
gemcitabine at 3nM had no effect on the removal of
melphalan-induced ICLs in A549 cells (Figure 4B). This
again suggests that the mechanisms of unhooking for
cisplatin and melphalan ICLs are distinct, with only the
former mechanism being inhibited by gemcitabine. The
mechanism by which gemcitabine inhibits the unhook-
ing of cisplatin ICLs remains unclear. Gemcitabine is
believed to inhibit nucleotide excision repair by incorp-
oration into repair patches thereby causing chain termin-
ation. One possible mechanism is that the nucleotide
excision repair of cisplatin-induced intrastrand adducts
is inhibited by incorporation of gemcitabine into repair
patches resulting in sequestering of repair proteins,
including those required for the initial unhooking step of
DNA ICLs.
The roles of homologous recombination and replication
The formation of RAD51 foci as a marker of homolo-
gous recombination in A549 and RPMI8226 cells was
examined following treatment with cross-linking agent
(Figure 5). Representative RAD51 images are shown in
Figure 5A. In A549 cells, a strong RAD51 foci response
followed the peak of ICL for melphalan and thendeclined rapidly (Figure 5B), similar to the γ-H2AX
response to this drug in this cell line (Figure 2D). The
response following cisplatin was, however, distinct in
that there was an initial peak at 4 hours with levels
decreasing to baseline at 8 hours followed by a second
late peak at 24 hours (Figure 5B). We have observed this
biphasic response to cisplatin in other cell types includ-
ing human leukaemic K562 cells and lymphocytes (data
not shown). In RPMI8226 cells the RAD51 response was
weak (Figure 5C), despite the formation of cross-links by
both agents. Homologous recombination activity has
been shown to be elevated in multiple myeloma cells
leading to an increased rate of mutation and progressive
accumulation of genetic variation over time [30]. Inter-
estingly, the basal expression levels of RAD51 mRNA
were 5-fold higher in RPMI8226 cells than in A549
as determined by real-time PCR (data not shown).
The lack of a significant RAD51 foci response to ICLs
in RPMI8226 cells is therefore not due to a lack of
RAD51 protein.
It might be expected that γ-H2AX and RAD51 foci
would form coincidentally. Both A549 and RPMI8226
cells can unhook melphalan-induced ICLs. In A549 cells
there is a strong γ-H2AX response, peaking with the for-
mation of ICLs and then declining rapidly. The RAD51
response follows the same time course. In contrast, in
RPMI8226 cells the γ-H2AX response to melphalan
ICLs is less than half that observed in A549 cells for the
equivalent peak level of ICLs and in RPMI8226 cells
there is no significant RAD51 response. The reasons for
the different responses are unclear, however the rapid
decrease in γ-H2AX foci in the RPMI8226 cells in the
absence of RAD51 foci suggests that resolution of
double strand breaks may not be by homologous recom-
bination repair in these cells.
The processing of ICLs may differ in replicating and
non-replicating cells [31]. We examined the ability of
isolated non-replicating human lymphocytes to unhook
cisplatin and melphalan-induced ICLs (Figure 5D). The
peak of cross-linking for both drugs was as observed in
the human tumour cell lines, and lymphocytes rapidly
unhooked the cross-links produced by both drugs.
Clearly, melphalan and cisplatin-induced ICLs can be
unhooked in both replicating and non-replicating cells.
Whether the mechanisms involved are the same is
unknown and warrants further investigation.
Table 1 Summary of the genes from A549 or RPMI8226
cells whose expression is changed more than two-fold
following peak ICL formation by ether melphalan or
cisplatin treatment compared to untreated controls
Gene Fold Regulation
A549 cells RPMI8226 cells
Melphalan
(50μM)
Cisplatin
(150μM)
Melphalan
(50μM)
Cisplatin
(150μM)
BTG2 4.86 9.29 −2.06 −1.35
HUS1 2.28 2.49 1.12 −2.77
LIG1 4.43 3.88 1.25 1.13
SESN1 5.71 12.47 1.50 −1.18
TREX1 3.41 5.89 −2.75 −1.27
DMC1 −2.41 −3.97 1.14 −2.16
GADD45A 1.39 2.43 1.64 1.88
PCBP4 1.76 2.66 −4.30 −3.21
PCNA 1.84 2.40 2.58 3.63
XPC 1.88 2.61 −1.60 −1.25
ATM −1.41 −2.09 1.21 −3.00
ATRX 1.1 −2.15 −1.52 −4.32
BRCA1 −1.24 −2.82 −1.16 −3.44
CHEK2 −1.15 −2.09 −1.24 −2.59
CIDEA −1.98 −3.33 −16.32 −4.33
GML −1.98 −3.33 −17.7 −5.77
MAP2K6 −1.61 −4.64 −1.87 −5.92
MNAT1 −1.03 −2.71 −1.23 −3.95
MSH3 1.1 −2.03 1.10 −2.75
RAD51L1 −1.58 −4.94 −3.94 −13.50
SMC1A −1.51 −2.01 1.10 −1.06
TP73 −1.97 −3.33 −1.57 −3.38
GTSE1 −1.64 −1.69 3.32 2.63
PRKDC −1.47 −1.97 2.10 1.11
ZAK 1.06 −1.84 3.52 −1.51
RPL13A −1.34 −1.18 3.10 3.58
DDIT3 1.61 1.92 −7.33 −4.31
IGHMBP2 −1.05 1.14 −2.28 −1.68
IP6K3 1.02 1.94 −16.66 −4.79
NBN 1.3 −1.16 −2.18 −3.11
PMS2L3 −1.56 −1.53 −3.50 −3.24
PPP1R15A −1.43 −1.06 −11.28 −3.52
RAD17 −1.46 −1.52 −2.21 −2.08
SEMA4A −1.97 −1.12 −2.17 −3.91
PMS1 −1.29 −1.69 −2.01 −2.92
EXO1 −1.06 1.32 1.60 2.73
FANCG 1.00 −1.06 1.65 2.27
FEN1 −1.03 1.35 1.29 2.03
ATR −1.54 −1.78 −1.18 −2.24
CHEK1 −1.73 −1.74 −1.08 −13.65
MRE11A 1.19 −1.06 −1.45 −2.78
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In order to look for possible factors which could explain
the different repair response we next examined by real
time PCR the effect on expression of 84 genes involved
in DNA damage signalling/repair pathways following ex-
posure of cells to ICL agent. Comparisons were made at
doses and times which gave an equivalent peak of ICL
(cisplatin: 150 μM, 1 hour followed by 9 hours post-
incubation; melphalan 50 μM, 1 hour followed by
16 hours). Figure 6 shows the results for A549 cells fol-
lowing melphalan (A) or cisplatin (B) treatment. In each
case the mean expression from three individual drug
treatment repeat samples are compared to three control
samples. Genes which show increased expression by
more than 2-fold compared to control cells following
drug treatment are shown in red and those which show
decreased expression in green. The genes that show
more than 2-fold altered expression in A549 cells and
RPMI8226 cells are detailed in Table 1. In A549 cells
only five genes (BTG2, HUS1, LIG1, SESN1 and TREX1)
show a greater than 2-fold increased expression follow-
ing melphalan (Figure 6A, Table 1). In this cell line the
same five genes exhibit increased expression after cis-
platin treatment (Figure 6B, Table 1) but, in addition,
four other genes (GAD45A, PCBP4, PCNA, XPC)
showed increased expression. The two genes showing
the greatest level of increased expression (SESN1 and
BTG2) were the same for the two drugs. The number of
genes that are decreased in expression by more than 2-
fold (green) was much greater for cisplatin (13) com-
pared to melphalan (1).
In RPMI8226 cells the pattern of altered expression is
distinct from A549 cells (Table 1). For melphalan, a dif-
ferent five genes had increased expression (PCNA, GTSE1,
PRKDC, ZAK, RPL13A), whereas for cisplatin six genes
showed increased expression (PCNA, GTSE1, RPL13A,
EXO1, FANCG, FEN1). In this cell line, neither SESN1
nor BTG2 was increased by either drug. Interestingly,
levels of expression of the DNA repair protein ERCC1 did
not change by more than two-fold in either cell line fol-
lowing either cross-linking agent, despite this protein hav-
ing a potential role in the unhooking step [5,15,16]. Cells
defective in this protein show extreme sensitivity to
both nitrogen mustard and platinum-based drugs [5,32].
Although the real time PCR data in the current study
highlight differences in the damage response to melphalan
and cisplatin in the two cell lines, no clear pattern emerges
which could explain the different response of the cells to
unhooking of cisplatin and melphalan ICLs.
Conclusions
Overall, these data provide conclusive evidence that the
mechanisms by which melphalan and cisplatin-induced
ICLs are ‘unhooked’ in vitro are distinct. Only the latter
Table 1 Summary of the genes from A549 or RPMI8226
cells whose expression is changed more than two-fold
following peak ICL formation by ether melphalan or
cisplatin treatment compared to untreated controls
(Continued)
RAD18 −1.31 −1.61 −1.33 −2.07
RAD50 1.32 −1.12 −1.11 −3.07
XRCC2 1.24 1.23 1.05 −3.66
Data are the mean from three individual drug treated and three control RNA
samples in each case. Genes more than two-fold upregulated are shown in
red and more than two-fold downregulated in green. For comparison the fold
regulation is shown for these genes in both cell lines following both
treatments with downregulation shown as negative numbers.
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http://www.biomedcentral.com/1471-2407/12/436mechanism is inhibited by gemcitabine. Importantly, the
observed mechanisms of clinical acquired drug resist-
ance in multiple myeloma to melphalan and in ovarian
cancer to cisplatin, which involve repair/unhooking of
ICLs, are shown to be specific to the individual drug.
This clearly has important clinical implications for the
treatment of drug-resistant disease.
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